AbbVie Inc. Working Capital

Working Capital of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.

Highlights and Quick Summary

  • Working Capital for the quarter ending June 29, 2020 was $-3.39 Billion (a -109.61% decrease compared to previous quarter)
  • Year-over-year quarterly Working Capital decreased by -226.82%
  • Annual Working Capital for 2019 was $33.9 Billion (a -11642.18% decrease from previous year)
  • Annual Working Capital for 2018 was $-294 Million (a -106.42% decrease from previous year)
  • Annual Working Capital for 2017 was $4.58 Billion (a -28.47% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of AbbVie Inc.

Most recent Working Capitalof ABBV including historical data for past 10 years.

Interactive Chart of Working Capital of AbbVie Inc.

AbbVie Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-3,390.0 $35,287.0
2019 $33,934.0 $2,673.0 $-1,841.0 $509.0 $33,934.0
2018 $-294.0 $3,078.0 $-3,379.0 $3,386.0 $-294.0
2017 $4,582.0 $5,897.0 $4,703.0 $6,703.0 $4,582.0
2016 $6,406.0 $7,187.0 $7,519.0 $5,960.0 $6,406.0
2015 $5,420.0 $9,099.0 $5,619.0 $4,358.0 $5,420.0
2014 $4,688.0 $10,920.0 $11,477.0 $11,113.0 $4,688.0
2013 $10,969.0 $9,668.0 $8,857.0 $8,157.0 $10,969.0
2012 $8,578.0 $5,562.85 $1,153.24 $1,236.09 $8,578.0
2011 $1,457.0 $1,457.0
2010 $4,457.25 $4,457.25

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.